Patents Represented by Attorney Edward L. Mandell
  • Patent number: 5192550
    Abstract: A dosage form is disclosed comprising an anti-Parkinson's disease drug for administering to a patient in need of anti-Parkinson's disease therapy.
    Type: Grant
    Filed: March 5, 1992
    Date of Patent: March 9, 1993
    Assignee: ALZA Corporation
    Inventors: David E. Edgren, Howard A. Carpenter, Gurdish K. Bhatti, Atul D. Ayer
  • Patent number: 5190765
    Abstract: A dosage form is disclosed comprising means for delaying the delivery of drug from the dosage form following the administration of the dosage form to a patient in need of drug therapy.
    Type: Grant
    Filed: November 26, 1991
    Date of Patent: March 2, 1993
    Assignee: ALZA Corporation
    Inventors: Frank Jao, Patrick S. L. Wong, Hoa T. Huynh, Kathy McChesney, Pamela K. Wat
  • Patent number: 5186942
    Abstract: A dosage form is disclosed comprising a member selected from the group consisting of nicardipine and its pharmaceutically acceptable salts for administering to a patient in need of cardio-vascular therapy.
    Type: Grant
    Filed: November 18, 1991
    Date of Patent: February 16, 1993
    Assignee: ALZA Corporation
    Inventors: Joseph C. Deters, David R. Swanson, Stephen C. DeRosa
  • Patent number: 5185158
    Abstract: A dosage form is provided for administering a drug of the formula ##STR1## to a patient to produce an anxiolytic benefit in the patient.
    Type: Grant
    Filed: February 27, 1992
    Date of Patent: February 9, 1993
    Assignee: ALZA Corporation
    Inventors: Atul Ayer, Dana Ridzon
  • Patent number: 5180591
    Abstract: This invention relates to an active agent delivery device. More particularly, the invention relates to a delivery device that includes a sleeve to protect the delivery device from transient mechanical forces. The delivery device of the invention is robust and resistant to transient mechanical forces. The invention provides a fluid-imbibing delivery device comprising a housing enclosing an internal compartment, said housing having a first wall section that substantially restricts the passage of fluid into the delivery device, i.e. is substantially fluid-impermeable, and that contains a beneficial agent; a second wall section that permits the passage of fluid into the delivery device, i.e. is fluid-permeable, and that contains at least one expandable driving member; and exit means; with a protective sleeve means extending from the first wall section of the housing to cover and protect the second wall section of the housing and the junction of the first and second sections.
    Type: Grant
    Filed: July 11, 1990
    Date of Patent: January 19, 1993
    Assignee: Alza Corporation
    Inventors: Judy A. Magruder, John R. Peery, James B. Eckenhoff
  • Patent number: 5176665
    Abstract: The invention pertains to a delivery system comprising a biocide, with the delivery system designed and shaped for passage through the exit port of a urine container into the container.
    Type: Grant
    Filed: January 18, 1991
    Date of Patent: January 5, 1993
    Assignee: Alza Corporation
    Inventors: Tyler Watanabe, Su I. Yum, Eun S. Lee, Ivan W. Chin
  • Patent number: 5174999
    Abstract: A delivery system is disclosed for delivering a beneficial agent to an animal. The delivery system comprises a wall that surrounds a lumen, said wall comprising a composition that limits the passage of fluid into the system and a composition that permits the passage of fluid into the system. The lumen comprises a beneficial agent and an expandable member. The delivery system comprises an exit means for delivering the beneficial agent.
    Type: Grant
    Filed: April 20, 1990
    Date of Patent: December 29, 1992
    Assignee: ALZA Corporation
    Inventors: Judy A. Magruder, James B. Eckenhoff, Richard Cortese, Jeremy C. Wright, John R. Peery
  • Patent number: 5171576
    Abstract: A method of preventing sensitization in transdermal drug delivery by the inclusion of a corticosteroid, which will be co-extensively coadministered with the sensitizing agent.
    Type: Grant
    Filed: August 30, 1991
    Date of Patent: December 15, 1992
    Assignee: ALZA Corporation
    Inventors: Alfred Amkraut, Jane E. Shaw
  • Patent number: 5169383
    Abstract: A membrane capable of controlling the rate at which an agent is released from an iontophoretic delivery device is provided. The membrane inhibits agent release from the delivery device when no electrical current is flowing and yet provides minimal impedance to electrically-assisted agent delivery. The membrane is useful both as a control membrane in an iontophoretic agent delivery device and as a test membrane for testing the performance characteristics of an iontophoretic agent delivery device in vitro.
    Type: Grant
    Filed: September 7, 1990
    Date of Patent: December 8, 1992
    Assignee: ALZA Corporation
    Inventors: J. Richard Gyory, Ronald P. Haak, Felix Theeuwes
  • Patent number: 5169382
    Abstract: A membrane capable of inhibiting agent release from a delivery system when no electrical current is flowing and yet provide minimal impedance to electrically-assisted agent delivery, useful both for incorporating into electrotransport agent delivery systems and for use in measuring agent release rates in in vitro testing.
    Type: Grant
    Filed: January 30, 1991
    Date of Patent: December 8, 1992
    Assignee: Alza Corporation
    Inventors: Felix Theeuwes, J. Richard Gyory, Ronald P. Haak
  • Patent number: 5167616
    Abstract: An improved method for delivering a drug or beneficial agent transdermally to humans by iontophoresis is provided. The method includes selecting and iontophoretically delivering the drug through a skin site which optimizes the transdermal delivery rate of the drug while minimizing inter-patient variability in skin resistance.
    Type: Grant
    Filed: December 14, 1989
    Date of Patent: December 1, 1992
    Assignee: Alza Corporation
    Inventors: Ronald P. Haak, J. Richard Gyory, Jane Yieh
  • Patent number: 5162043
    Abstract: An iontophoretic agent delivery device having donor and counter electrodes comprised of either metal or a hydrophobic polymer loaded with a conductive filler is provided. The agent reservoir in the donor electrode assembly contains about 10 to 60 wt % hydrophobic polymer, about 10 to 60 wt % hydrophilic polymer, and up to 50% agent. Similarly, the electrolyte reservoir contains about 10 to 60 wt % hydrophobic polymer, about 10 to 60 wt % hydrophilic polymer, and up to 50% electrolyte. The agent reservoir, the electrolyte reservoir and the electrodes are preferably in the form of films which are laminated to one another. The hydrophobic polymer component in the agent/electrolyte reservoir prevents the reservoir from delaminating from the metal/hydrophobic polymer based electrode, even after hydration of the reservoirs.
    Type: Grant
    Filed: November 6, 1991
    Date of Patent: November 10, 1992
    Assignee: Alza Corporation
    Inventors: Patrick J. Lew, J. Richard Gyory
  • Patent number: 5162042
    Abstract: A transdermal therapeutic system which utilizes electrical current to facilitate drug delivery.
    Type: Grant
    Filed: December 27, 1991
    Date of Patent: November 10, 1992
    Assignee: Alza Corporation
    Inventors: J. Richard Gyory, Ronald P. Haak, Felix Theeuwes
  • Patent number: 5160741
    Abstract: The present invention provides a method of reducing or preventing skin irritation of a weak base drug by inhibiting the accumulation of the drug in the lysosomes. The drug is irritating to humans, i.e., the drug is susceptible to inducing skin or mucosa irritation in a human when the drug is transdermally administered to the human at a therapeutically effective rate. Irritation reduction or prevention is induced by coadministering to the skin or mucosa of the human:(a) a therapeutically effective amount of a weak base drug which is irritating to humans, at a therapeutically effective rate over a predetermined period of time; and(b) an effective amount of an agent capable of inhibiting the lysosomal uptake of the drug to reduce or prevent irritation to the skin or mucosa.
    Type: Grant
    Filed: November 13, 1991
    Date of Patent: November 3, 1992
    Assignee: ALZA Corporation
    Inventors: Michel J. N. Cormier, Philip W. Ledger, Alfred Amkraut
  • Patent number: 5160744
    Abstract: A dosage form is disclosed comprising means for delaying the delivery of drug from the dosage form following the administration of the dosage form to a patient in need of drug therapy.
    Type: Grant
    Filed: June 27, 1991
    Date of Patent: November 3, 1992
    Assignee: Alza Corporation
    Inventors: Frank Jao, Patrick S. Wong, Hoa T. Huynh, Kathy McChesney, Pamela K. Wat
  • Patent number: 5160320
    Abstract: An agent formulator (30, 60) for an intravenous administration set (14) is provided. The intravenous administration set (14) includes a container (12) of an IV fluid (13), a drip chamber (22), an agent formulator (30, 60) and an adapter-needle assembly (28). The agent formulator (30, 60) has a fluid inlet (23) and a fluid outlet (25) for maintaining a flow of IV fluid (13 ) therethrough. A portion (36) of the formulator wall (32) is comprised of a window material which allows the agent to diffuse therethrough but which prevents convective loss of the IV fluid (13). A flow distributor (38, 68) is provided within the chamber for distributing the flow of IV fluid (13) along the interior surface of the window (36). A transdermal-type drug delivery device (40) is adhered to the exterior surface of the window (36). Drug is delivered by the delivery device (40) through the window (36) and into the flowing IV fluid (13).
    Type: Grant
    Filed: August 12, 1991
    Date of Patent: November 3, 1992
    Assignee: Alza Corporation
    Inventors: Su I. Yum, Felix Theeuwes
  • Patent number: 5158537
    Abstract: A dry-state iontophoretic drug delivery device (10, 70, 80) is provided. The device has drug and electrolyte reservoirs (15, 16) which are initially in a non-hydrated condition. A liquid-containing pouch (21, 22) is provided. In certain embodiments the liquid is contained in breakable capsules within the pouch. Water or other liquid can be released from the capsules in the pouch by squeezing or flexing the pouches (21, 22). Alternatively, the liquid can be released from the pouches (21, 22) using pouch piercing pins (36, 37). The liquid released from the pouches (21, 22) hydrates the drug and electrolyte reservoirs (15, 16) and activates the device. In another embodiment, the device (20, 20a) has liquid-containing gel layers (31, 32) which are initially separated from their respective electrode assemblies (8, 9). Liquid-wicking pathways (27, 28) are provided to carry the liquid from the gel layers (31, 32) to the drug and electrolyte layers (15, 16).
    Type: Grant
    Filed: October 29, 1990
    Date of Patent: October 27, 1992
    Assignee: Alza Corporation
    Inventors: Ronald P. Haak, J. Richard Gyory, Felix Theeuwes, Felix A. Landrau, Nathan Roth, Robert M. Myers
  • Patent number: 5156850
    Abstract: A dosage form is disclosed that comprises means inside the dosage form for providing a substantially drug-free interval before the dosage form delivers a drug from inside the dosage form. The dosage form in an embodiment comprises a drug on the exterior of the dosage form, which drug is available for immediate delivery.
    Type: Grant
    Filed: August 31, 1990
    Date of Patent: October 20, 1992
    Assignee: ALZA Corporation
    Inventors: Patrick S. Wong, Felix Theeuwes, Atul D. Ayer, Anthony L. Kuczynski
  • Patent number: 5151093
    Abstract: An osmotically driven syringe (20, 60) is disclosed which can be used to deliver a beneficial agent such as a drug, at varying pre-determined rates over multiple periods of time. The syringe (20, 60) is driven by an osmotic engine (10) having a shaped wall (12) containing an osmotic agent (17) and/or a gas generating means (19), such as an effervescent couple. The wall (12) is composed of a semipermeable and/or microporous material which is permeable to an external liquid (e.g., water) but which is substantially impermeable to the osmotic agent (17) and the gas generated by the gas generating means (19). The wall (12) has a passageway (13) therethrough to provide a flow path for the driving fluid generated by the engine (10). The osmotic agent(s) (17) and/or the gas generating means (19) are placed in the engine (10) in such a way as to drive engine (10) at different pumping rates (R.sub.1, R.sub.2) over sequential periods of time (t.sub.o to t.sub.1 and t.sub.1 to t.sub.2).
    Type: Grant
    Filed: October 29, 1990
    Date of Patent: September 29, 1992
    Assignee: Alza Corporation
    Inventors: Felix Theeuwes, Su I. Yum
  • Patent number: 5149539
    Abstract: The present invention is directed to a method of reducing or preventing skin sensitization by inhibiting the immunological processing of a sensitizing drug as an antigen. The drug is sensitizing to humans, i.e., the drug is susceptible to inducing skin or mucosa sensitization in a human when the drug is transdermally administered to the human at a therapeutically effective rate. Skin sensitization reduction or prevention is induced by coadministering to the skin or mucosa of the human:(a) a therapeutically effective amount of a sensitizing drug, at a therapeutically effective rate over a predetermined period of time; and(b) an antigen processing-inhibiting agent in an amount effective to inhibit the antigen processing of the drug.The system of the invention comprises a matrix adapted to be placed in sensitizing drug and antigen processing-inhibiting agent transmitting relation to the selected skin or mucosa site.
    Type: Grant
    Filed: November 15, 1991
    Date of Patent: September 22, 1992
    Assignee: ALZA Corporation
    Inventors: Philip W. Ledger, Michel J. N. Cormier, Alfred Amkraut